Physicians' Academy for Cardiovascular Education
Prof. Lam talks about effects of SGLT2i in HF across the spectrum of LVEF and reviews current guideline treatment recommendations.
Javed Butler and Shelley Zieroth talk about the effects and tolerability of SGLT2i and the oral soluble guanylate cyclase stimulator vericiguat in patients with HFrEF.
The American Diabetes Association (ADA) has made important updates to the Standard of Medical Care in Diabetes 2022. Updates include new data on finerenone in T2DM and CKD, SGLT2i in T2DM and calculating eGFR.
Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.
Hyperkalemia frequently leads to the interruption or discontinuation of treatment with RAAS inhibitors, which may worsen the prognosis of patients with HF. The SGLT2 inhibitor empagliflozin may offer relief here.
By pooling data from 20 RCTs, researchers analyzed the adverse event rate with empagliflozin versus placebo in 2367 T2DM patients with moderate to severe CKD.
Although American cardiologists are increasingly prescribing SGLT2is and GLP‐1RAs since 2015, they accounted for <2% of all use in 2020. This could contribute to the known undertreatment of T2DM patients with high CVD risk.
ESC Heart Failure 2022 An analysis of the EMPULSE trial investigated the decongestive effects of empagliflozin compared with placebo in addition to standard medical treatment.
ESC Heart Failure 2022 A randomized clinical trial investigated the effect of dapagliflozin on maximal functional capacity at 1 and 3 months in patients with stable HFrEF.
ESC Heart Failure 2022 A pooled patient-level analysis of DEFINE-HF and PRESERVED-HF investigated the effect of dapagliflozin on symptoms and physical limitations across the range of LVEF.
A significant reduction in the primary composite endpoint of CV death or worsening HF was reached with dapagliflozin in HF patients with LVEF >40% in the DELIVER phase III trial.
A secondary analysis of the EMPEROR-Preserved shows that empagliflozin reduces the primary outcome regardless of background mineralocorticoid receptor antagonists (MRA) therapy. Reduction of total HF hospitalization was more pronounced in MRA nonusers.
